These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12376037)

  • 1. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
    Gotfried M; Quinn TC; Gothelf S; Wikler MA; Webb CD; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):85-91. PubMed ID: 12376037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.
    Jones RN; Andes DR; Mandell LA; Gothelf S; Ehrhardt AF; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):93-100. PubMed ID: 12376038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.
    Nicholson SC; Wilson WR; Naughton BJ; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):117-25. PubMed ID: 12376041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
    Sher LD; Poole MD; Von Seggern K; Wikler MA; Nicholson SC; Pankey GA
    Otolaryngol Head Neck Surg; 2002 Sep; 127(3):182-9. PubMed ID: 12297808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
    Nicholson SC; Webb CD; Andriole VT; Jones RN; Wilson WR
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):101-7. PubMed ID: 12376039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.
    Nicholson SC; High KP; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):109-16. PubMed ID: 12376040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis.
    Anzueto A; Gotfried M; Wikler MA; Russo R; Nicholson SC
    Clin Ther; 2002 Jun; 24(6):906-17. PubMed ID: 12117081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.
    Nicodemo AC
    Braz J Infect Dis; 2003 Feb; 7(1):62-8. PubMed ID: 12807692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S
    Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.
    Mandell LA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):127-8. PubMed ID: 12376042
    [No Abstract]   [Full Text] [Related]  

  • 13. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).
    Mandell LA
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):65-7. PubMed ID: 12376034
    [No Abstract]   [Full Text] [Related]  

  • 16. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study.
    Leibovitz E; Piglansky L; Raiz S; Greenberg D; Hamed KA; Ledeine JM; Press J; Leiberman A; Echols RM; Pierce PF; Jacobs MR; Dagan R
    Pediatr Infect Dis J; 2003 Nov; 22(11):943-9. PubMed ID: 14614364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
    Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.
    Smayevsky J; Lopez H; Di Chiara M; Scarano S; Lanza A; Vilches V; Stepanik D; Bantar C; Sucari A
    Diagn Microbiol Infect Dis; 2000 Aug; 37(4):261-4. PubMed ID: 10974577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.